Dermatologic Toxicity Dermatologic toxicities

Related by string. * dermatologic : ERBITUX dermatologic toxicities . Doak Dermatologics subsidiary . dermatologic toxicity / TOXICITY . toxicity : mitochondrial toxicity . morphine toxicity . hematologic toxicity correlated / : Doak Dermatologics specializing . Doak Dermatologics . severe dermatologic toxicities / Toxicities : hematologic toxicities . non hematological toxicities * *

Related by context. Frequent words. (Click for all words.) 62 laboratory abnormalities 55 serum calcium 55 cytogenetic response 54 acneform rash 54 virologic failure 54 myocardial infarctions 54 SAEs 54 platelet reactivity 53 events SAEs 53 leukopenia 52 estimated glomerular filtration 52 HSCT 52 seroprotection 51 vertebral fracture 51 grade gliomas 51 nondiabetic 51 hypoglycemic events 51 NHANES III 51 Medication errors 50 virologic response 50 % CI #.#-#.# [003] 50 creatinine levels 50 nonobese 50 p = .# [002] 50 biochemical recurrence 50 heavily pretreated 50 patients evaluable 50 de ath 50 unknown etiology 49 neuropsychiatric symptoms 49 serum PSA 49 fasting insulin 49 C. difficile infections 49 ADHD RS 49 dose cohorts 49 thrombotic events 49 Hospitalizations 48 LVEF 48 antibody titers 48 Urinary tract infections 48 adenocarcinomas 48 congenital malformations 48 untreated tooth decay 48 Median survival 48 HbA1c levels 48 elevated triglycerides 48 seroconversion 47 CI #.#-#.# [002] 47 HbA 1c 47 squamous 47 lymph node involvement 47 serum concentrations 47 angiotensin converting enzyme inhibitors 47 A1C levels 47 relapsing remitting 47 sustained virologic response 46 nasopharyngitis 46 lymph node metastases 46 nonadherence 46 mineral density 46 liver transplant recipients 46 T2DM 46 carcinoid 46 glycated hemoglobin 46 Malignant gliomas 46 Researchers randomly assigned 46 subanalysis 46 HRQoL 45 nonoperative 45 coinfected 45 highest quintile 45 evaluable 45 PSAE 45 histologic 45 reach statistical significance 45 univariate analysis 45 antihypertensive medications 45 congenital anomalies 45 ischemic cardiomyopathy 45 composite endpoint 45 Secondary endpoints included 44 hemoglobin concentration 44 placebo controlled studies 44 ICM interviewed 44 dose regimens 44 NYHA class 44 multivariate analyzes 44 MetS 44 subtests 44 ADAS cog 44 insulin glargine 44 hemoglobin A1C 43 Payable Apr 43 antihypertensive agents 43 Fatal crashes 43 haemorrhagic 43 hsCRP 43 comorbid conditions 43 prespecified 43 proteinuria 43 rheumatoid factor

Back to home page